UNSPSC 51384516: Pranoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2R7O1ET613, chemically known as 5h-(1)benzopyrano(2,3,-b)pyridine-7-acetic acid, alpha-methyl- but generally known as pranoprofen, which bears US NIH Compound Identifier 4888. European Medicines Agency schedules Pranoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10000MIG.

UNSPSC 51384516 Pranoprofen, a Commodity code, does not reflect the work state and local governments are actually procuring under this classification. The single recent opportunity tagged to this code—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—is unrelated to pranoprofen, an anti-inflammatory pharmaceutical. The mismatch suggests either a tagging error in the source data or minimal legitimate procurement activity under the pranoprofen code in the state and local market. Pranoprofen, when procured by public health agencies, would typically fall within pharmaceutical supply chains for specific clinical or emergency-response applications, but no such opportunities appear in recent postings.

Seminole County's July 2026 IFB (IFB60459723LAS, response deadline July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement was potentially FEMA-funded and required E-Verify compliance, drug-free workplace certification, and standard insurance coverages. Without additional recent opportunities tied directly to pranoprofen procurement, the code shows no identifiable activity in the state and local market at this time.